- Home
- SBFG vs ENLV Comparison
SBFG vs ENLV Comparison
Compare SBFG & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | ENLV |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.9M | 149.0M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SBFG | ENLV |
|---|---|---|
| Price | $23.25 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 24.3K | ★ 431.3K |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.05 | $0.57 |
| 52 Week High | $25.05 | $2.10 |
Technical Indicators
Market Signals| Indicator | SBFG | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 30.26 |
| Support Level | $20.94 | N/A |
| Resistance Level | $23.93 | $1.23 |
| Average True Range (ATR) | 0.89 | 0.06 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 57.03 | 10.51 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.